Temporal footprint reduction via neural network denoising in 177Lu radioligand therapy

Internal vectorised therapies, particularly with [177Lu]-labelled agents, are increasingly used for metastatic prostate cancer and neuroendocrine tumours. However, routine dosimetry for organs-at-risk and tumours remains limited due to the complexity and time requirements of current protocols.

We developed a Generative Adversarial Network (GAN) to transform rapid 6 s SPECT projections into synthetic 30 s-equivalent projections. SPECT data from twenty patients and phantom acquisitions were collected at multiple time-points.

The GAN accurately predicted 30 s projections, enabling estimation of time-integrated activities in kidneys and liver with maximum errors below 6 % and 1 %, respectively, compared to standard acquisitions. For tumours and phantom spheres, results were more variable. On phantom data, GAN-inferred reconstructions showed lower biases for spheres of 20, 8, and 1 mL (8.2 %, 6.9 %, and 21.7 %) compared to direct 6 s acquisitions (12.4 %, 20.4 %, and 24.0 %). However, in patient lesions, 37 segmented tumours showed higher median discrepancies in cumulated activity for the GAN (15.4 %) than for the 6 s approach (4.1 %).

Our preliminary results indicate that the GAN can provide reliable dosimetry for organs-at-risk, but further optimisation is needed for small lesion quantification. This approach could reduce SPECT acquisition time from 45 to 9 min for standard three-bed studies, potentially facilitating wider adoption of dosimetry in nuclear medicine and addressing challenges related to toxicity and cumulative absorbed doses in personalised radiopharmaceutical therapy.